Armata Pharmaceuticals Inc (ARMP) Stock Analysis
Verdict: AVOID
Critical cash runway of ~4 months and $288M debt outweigh FDA Breakthrough status, creating severe dilution risk.
Investment score: 24/100
Analysis as of
Is Armata Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assesses Armata Pharmaceuticals as an AVOID due to severe cash burn, a balance sheet featuring $288.02M in total debt against negative equity, and an estimated cash runway of under 4 months. Although FDA Breakthrough Therapy designation for AP-SA02 provides clinical validation, upcoming capital raises pose extreme dilution risks for existing shareholders.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Armata Pharmaceuticals Inc opportunities and risks
What speaks for ARMP
- FDA Breakthrough Therapy Designation for AP-SA02
What speaks against ARMP
- Imminent Cash Exhaustion and High Dilution Risk
Peers and competitors
- CNTN
- MNOV
- RNA
- HUMA
- SPRB
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ARMP | n/a | 46.7x | n/a | 68.2% | -5825.3% | -16.7% |
| CNTN | n/a | 109.6x | n/a | 100.0% | -6559.3% | -13.5% |
| MNOV | n/a | 174.6x | n/a | 42.4% | -1168.2% | -1199.2% |
| RNA | n/a | 7.0x | n/a | 97.9% | -396.5% | -35.1% |
| HUMA | n/a | 46.3x | n/a | -666.8% | -4560.8% | -99.4% |
| SPRB | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.5% |
| Peer median | n/a | 46.3x | n/a | 42.4% | -1168.2% | -35.1% |
Frequently asked questions about Armata Pharmaceuticals Inc (ARMP)
Is ARMP stock a good investment?
The TradeMates model rates Armata Pharmaceuticals Inc as AVOID with an investment score of 24/100. The TradeMates model assesses Armata Pharmaceuticals as an AVOID due to severe cash burn, a balance sheet featuring $288.02M in total debt against negative equity, and an estimated cash runway of under 4 months. Although FDA Breakthrough Therapy designation for AP-SA02 provides clinical validation, upcoming capital raises pose extreme dilution risks for existing shareholders. This is algorithmic model output, not personal investment advice.
Is ARMP stock a buy?
The TradeMates model verdict for ARMP is AVOID with an investment score of 24/100. Treat this as a model signal to review, not a personal buy recommendation.